Risk and outcome in metastatic malignant melanoma patients receiving DTIC, cisplatin, BCNU and tamoxifen followed by immunotherapy with interleukin 2 and interferon alpha2a (Q36115587)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Risk and outcome in metastatic malignant melanoma patients receiving DTIC, cisplatin, BCNU and tamoxifen followed by immunotherapy with interleukin 2 and interferon alpha2a |
scientific article |
Statements
1 reference
Risk and outcome in metastatic malignant melanoma patients receiving DTIC, cisplatin, BCNU and tamoxifen followed by immunotherapy with interleukin 2 and interferon alpha2a (English)
1 reference
Hoffmann R
1 reference
Müller I
1 reference
Neuber K
1 reference
Lassmann S
1 reference
Buer J
1 reference
Probst M
1 reference
Oevermann K
1 reference
Franzke A
1 reference
Kirchner H
1 reference
Ganser A
1 reference
Atzpodien J
1 reference
1 October 1998
1 reference
1 reference
1076-1080
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
Identifiers
1 reference
1 reference
1 reference